Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Business & Regulation Bioprocessing - Single Use Systems, Business Practice

Top Pharma Headlines of 2022: The Story So Far

PhRMA and drug pricing

PhRMA kicked off the new year with a rebuttal in the ongoing drug pricing war in the US. The association funded a study to examine the drug supply chain – particularly distribution and payment processes. The findings? Manufacturers retain 49.5 percent of the sale of brand medicines (dropping to 37 percent when taking brand and generic medicines into account), with the rest going to PBMs, insurers, hospitals, pharmacies and even the government, among others. Between 2013 and 2020, the share of total brand spending retained by drug manufacturers fell by just over 17 percent.

Meanwhile during the same period the amount hospitals and other 340B entities received from the sale of brand medicines purchased via the 340B program grew by 1100 percent.

You can read the full analysis from the Berkeley Research Group here.

In the PhRMA statement, Stephen J Ubl says, “It’s time that policymakers accurately diagnose the problems that exist across the supply chain and the challenges patients actually experience. We must address what is really driving up costs for patients, like when middlemen are paid based on the list price of a medicine and when insurers refuse to share savings with patients at the pharmacy counter. We also must fix the 340B program, which has enabled hospitals to profit without assurances that patients see any benefit.”

Medicare blow to Biogen

The contention continues over Biogen’s Alzheimer’s drug, Aduhlem. The Centers for Medicare & Medicaid Services has proposed to provide insurance coverage for mAbs that target amyloid plaques – but only for patients enrolled in qualifying clinical trials. CMS acknowledges the potential for “promise” with the new treatment, but also the potential for harm due to the risk of severe side effects, such as brain bleeds. The final decision will be made in April 2022 and CMS has invited the public to submit comments.

As to be expected, Biogen isn’t happy with the decision and will be making a formal response. “It is imperative to change this draft decision to be aligned with reimbursement for other therapies for progressive diseases, where patients have immediate and equal access to medicines approved by the FDA,” the company said in a statement.

New mRNA horizons

Pfizer and BioNTech have set their sights on a new mRNA vaccine – this time for shingles. Under the new agreement, the companies will leverage some of the same technologies used in their COVID-19 vaccine. Clinical trials are planned to kick off in 2022 and the companies will share the development costs. In a joint statement, the companies said that: “Adults aged 50 years and older as well as vulnerable populations like cancer patients are at an increased risk of shingles.” Could this be an indicator of the patient populations that will be targeted by the proposed vaccine?

Pfizer has also made other announcements regarding mRNA; the company has signed a Development and Option agreement with Acuitas Therapeutics to develop nanoparticle delivery system for use in mRNA vaccines and therapeutics.

Single-use tech and the environment

How bad are single use technologies for the environment? There’s little research in the area, which makes this open access paper a highly interesting read. The paper performs a life cycle assessment for a mAb made via a single use manufacturing process and, among other findings, concludes that the “contribution to the environmental footprint from end-of-life due to the use of plastic SUT was extremely small.” According to the authors, the best strategies for reducing lifecycle environmental impact are operational changes that increase process efficiency and decrease time in plant.

What else is going on?

Here’s a selection of other interesting announcements to have come out of the industry so far in 2022

Moderna and Carisma agree to combine engineered macrophage tech with mRNA and LNP tech to develop engineered chimeric antigen receptor monocytes for oncology indications

Clarivate releases report ‘Drugs to Watch 2022’ covering key areas including cell and gene, CRISPR, RNA, targeted cancer therapeutics, and drug discovery driven by AI

Preliminary data show COVID-19 vaccines remain effective against Omicron variant and severe disease, according to the EMA

Merck KGaA strengthens CDMO mRNA offering with acquisition of Exelead for around $780 million

US government purchases 600,000 additional doses of sotrovimab for COVID-19 from GSK and Vir Biotechnology

Viatris wins US court decision as US Court of Appeals upholds unpatentability of certain device patents for Sanofi’s Lantus SoloSTAR


Want to keep up to date with news from the biopharma industry? Sign up to our fuss-free newsletter, The Bioprocess Curator.

We also have a dedicated newsletter for cutting edge cell and gene therapies: The Cell + Gene Curator.

Accelerating Manufacturing for Next Generation hiPSC-Based Therapies

hiPSC-based therapies are advancing at a rapid pace. In this on-demand webinar, learn what key criteria a cell therapy developer should use in selecting starting material for hiPSC generation, and insights into expansion and differentiation of hiPSC in large-scale production.

Watch Now

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine